CPHI Americas 2026 is set to return to Philadelphia from June 2-4, focusing on regulatory changes, AI integration, and advancements in biotechnology.
This annual conference serves as a vital networking platform for professionals across the pharmaceutical supply chain, including manufacturers, biotech firms, and service providers. Attendees will engage in discussions aimed at addressing key challenges facing the industry, with a particular emphasis on evolving regulatory frameworks and the impact of artificial intelligence on drug development.
Highlights of the agenda include sessions addressing the unpredictable regulatory landscape, featuring insights from experts like Molly Klote, and strategies for managing risks in global supply chains. Additionally, discussions will delve into the accelerating investment in biologics, with topics such as the future of biotech innovation and funding strategies led by prominent industry figures.
As the conference aims to tackle pressing issues like digitalization and cybersecurity, participants can expect sessions on safeguarding supply chains and leveraging AI in drug discovery. The focus on these critical areas underscores the conference's relevance in a rapidly evolving market, providing attendees with actionable insights to enhance their organizational strategies.
The emphasis on regulatory shifts, AI, and biologics at CPHI Americas 2026 reflects the industry's need to adapt to changing dynamics and maintain competitive advantage. This event promises to be instrumental for stakeholders looking to navigate the complexities of drug development and manufacturing.